Zhi Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zhi Yang has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Xiaoan Li
NHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China
4 shared publications Huiyi Feng
School of Modern Chinese Medicine Industry, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
3 shared publications- Xuemin Jian
NHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China
3 shared publications - Yuan Yin
NHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China
3 shared publications Ting Chen
School of Animal Science, Xichang University, Xichang, China
2 shared publicationsYu Long
NHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China
2 shared publications
Latest Publications
- 8 August 2026
- Published by Elsevier in Ageing Research Reviews
- Vol. 121, 103291
Metabolic reprogramming-driven neuroimmunoregulation: Key mechanisms and therapeutic opportunities and challenges in central nervous system disorders
- 8 August 2026
- Published by Elsevier in Ageing Research Reviews
- Vol. 121, 103291
Metabolic reprogramming-driven neuroimmunoregulation: Key mechanisms and therapeutic opportunities and challenges in central nervous system disorders
- Open Access
- 1 July 2026
- Published by Elsevier in Materials Today Bio
- Vol. 39
PROTAC-based nanoassemblies targeting BRD4 for potentiate FLASH radiosensitization therapy
- 1 July 2026
- Published by Elsevier in Materials Today Bio
- Vol. 39
Open AccessPROTAC-based nanoassemblies targeting BRD4 for potentiate FLASH radiosensitization therapy
- Open Access
- 7 November 2025
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 13, 1729877
Correction: Biomimetic membrane nanotechnology in cerebral ischemic stroke: a promising technology for therapeutic treatment and diagnosis
Correction on: Long Y, Zou Z, Wu Y, Feng H, Chen T, Yang Z, Jian X, Yin Y and Li X (2025) The original version of this article has been updated.
- 7 November 2025
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 13, 1729877
Open AccessCorrection: Biomimetic membrane nanotechnology in cerebral ischemic stroke: a promising technology for therapeutic treatment and diagnosis
Correction on: Long Y, Zou Z, Wu Y, Feng H, Chen T, Yang Z, Jian X, Yin Y and Li X (2025) The original version of this article has been updated.
- Open Access
- 20 August 2025
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 13, 1605377
Biomimetic membrane nanotechnology in cerebral ischemic stroke:a promising technology for therapeutic treatment and diagnosis
Cerebral ischemic stroke (CIS) is a severe cerebrovascular disease that poses numerous challenges in diagnosis and treatment, primarily attributed to blood-brain barrier (BBB) constraints and inherent drug targeting limitations. Biomimetic membrane nanotechnology, as an emerging therapeutic approach, offers a novel therapeutic strategy by emulating biological membrane structures and functions. This review comprehensively examines biomimetic nanomedicines (BMNPs) in CIS management, encompassing preparation methodologies, material characterization, and specific diagnostic/therapeutic applications. We discussed in detail various types of biomimetic nano-materials such as conventional extracellular membranes, bacterial outer membranes, and virus-like particles, and explore their capacity in enhancing BBB penetration, improving target specificity, and evading immune clearance. Current challenges regarding biosafety profiles, manufacturing quality control, targeted modification precision, and controlled drug release kinetics are delineated in this review. Looking to the future, advancing synergies between nanotechnology and biomedicine hold significant promise for optimizing CIS theranostics and expanding clinical treatment modalities.
- 20 August 2025
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 13, 1605377
Open AccessBiomimetic membrane nanotechnology in cerebral ischemic stroke:a promising technology for therapeutic treatment and diagnosis
Cerebral ischemic stroke (CIS) is a severe cerebrovascular disease that poses numerous challenges in diagnosis and treatment, primarily attributed to blood-brain barrier (BBB) constraints and inherent drug targeting limitations. Biomimetic membrane nanotechnology, as an emerging therapeutic approach, offers a novel therapeutic strategy by emulating biological membrane structures and functions. This review comprehensively examines biomimetic nanomedicines (BMNPs) in CIS management, encompassing preparation methodologies, material characterization, and specific diagnostic/therapeutic applications. We discussed in detail various types of biomimetic nano-materials such as conventional extracellular membranes, bacterial outer membranes, and virus-like particles, and explore their capacity in enhancing BBB penetration, improving target specificity, and evading immune clearance. Current challenges regarding biosafety profiles, manufacturing quality control, targeted modification precision, and controlled drug release kinetics are delineated in this review. Looking to the future, advancing synergies between nanotechnology and biomedicine hold significant promise for optimizing CIS theranostics and expanding clinical treatment modalities.